Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Cantor Fitzgerald
Daiichi Sankyo
Argus Health

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,517,181

« Back to Dashboard

Summary for Patent: 4,517,181

Title: Mammalian PGRF
Abstract:PGRF has been synthesized. The invention provides synthetic peptides which are extremely potent in stimulating the release of pituitary GH in mammals and which have the formula: ##STR1## wherein R is OH or NH.sub.2, R.sub.34 is Ser or Ala, R.sub.38 is Arg or Ser, R.sub.40 is Ala or Arg and R.sub.41 is Arg, Arg-Ala, Arg-Ala-Arg, Arg-Ala-Arg-Leu or des-R.sub.41. These peptides or biologically active fragments thereof, or analogs thereof having well-known substitutions and/or additions, as well as nontoxic salts of any of the foregoing, may be administered therapeutically to mammals, including humans, and may be used diagnostically.
Inventor(s): Ling; Nicholas C. (San Diego, CA), Esch; Frederick S. (Oceanside, CA), Bohlen; Peter (Encinitas, CA), Brazeau, Jr.; Paul E. (San Diego, CA), Guillemin; Roger C. L. (La Jolla, CA)
Assignee: The Salk Institute for Biological Studies (San Diego, CA)
Application Number:06/418,248
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

No matches for this query

International Patent Family for Patent: 4,517,181

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria17737► Subscribe
Australia1584383► Subscribe
Australia548590► Subscribe
Bulgaria37523► Subscribe
Canada1247599► Subscribe
Czech Republic281507► Subscribe
Czech Republic8304357► Subscribe
German Democratic Republic217808► Subscribe
Germany3362003► Subscribe
Denmark162649► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
Argus Health
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: